87 related articles for article (PubMed ID: 25298357)
1. [Genetic determinants of response to vitamin K antagonists].
Mundi S; Distante A; De Caterina R
G Ital Cardiol (Rome); 2014 Sep; 15(9):482-93. PubMed ID: 25298357
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacogenetic algorithms for predicting the appropriate dose of vitamin K antagonists: are they still useful?].
Mundi S; Distante A; De Caterina R
G Ital Cardiol (Rome); 2014 Oct; 15(10):546-60. PubMed ID: 25424019
[TBL] [Abstract][Full Text] [Related]
3. Influence of proton pump inhibitors and VKORC1 mutations on CYP2C9-mediated dose requirements of vitamin K antagonist therapy: a pilot study.
Brunner-Ziegler S; Jilma B; Magirr D; Sunder-Plassmann R; Giurgea GA; Hammer A; Margeta C; Brunner M; Koppensteiner R; Mannhalter C
Br J Haematol; 2014 Nov; 167(4):547-53. PubMed ID: 25142093
[TBL] [Abstract][Full Text] [Related]
4. Genetic, clinical and behavioural determinants of vitamin K-antagonist dose--explored through multivariable modelling and visualization.
Skov J; Bladbjerg EM; Rasmussen MA; Sidelmann JJ; Leppin A; Jespersen J
Basic Clin Pharmacol Toxicol; 2012 Feb; 110(2):193-8. PubMed ID: 21895980
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacogenomics of vitamin K antagonists].
Guzmán N; Vega M; Reyes F; Guzmán-Oyarzo D; Andaur M; Boguen R; Letelier P
Rev Med Chil; 2020 Sep; 148(9):1307-1314. PubMed ID: 33399707
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics of vitamin K antagonists: useful or hype?
Lippi G; Franchini M; Favaloro EJ
Clin Chem Lab Med; 2009; 47(5):503-15. PubMed ID: 19397481
[TBL] [Abstract][Full Text] [Related]
7. Impact of genetic and clinical factors on dose requirements and quality of anticoagulation therapy in Polish patients receiving acenocoumarol: dosing calculation algorithm.
Wolkanin-Bartnik J; Pogorzelska H; Szperl M; Bartnik A; Koziarek J; Bilinska ZT
Pharmacogenet Genomics; 2013 Nov; 23(11):611-8. PubMed ID: 24108193
[TBL] [Abstract][Full Text] [Related]
8. Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes: comment.
Gaikwad T; Ghosh K; Shetty S
J Thromb Haemost; 2017 Aug; 15(8):1708. PubMed ID: 28608988
[No Abstract] [Full Text] [Related]
9. Genotype-guided coumarin dosing: where are we now and where do we need to go next?
Baranova EV; Verhoef TI; Asselbergs FW; de Boer A; Maitland-van der Zee AH
Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):509-22. PubMed ID: 25595525
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of warfarin: current status and future challenges.
Wadelius M; Pirmohamed M
Pharmacogenomics J; 2007 Apr; 7(2):99-111. PubMed ID: 16983400
[TBL] [Abstract][Full Text] [Related]
11. [Impact of pharmacogenetics on interindividual variability in the response to vitamin K antagonist therapy].
Siguret V
Pathol Biol (Paris); 2007 Jul; 55(6):295-8. PubMed ID: 17611042
[TBL] [Abstract][Full Text] [Related]
12. [The pharmacogenetics of vitamin K antagonists: still a matter for discussion].
Moreau C; Siguret V; Loriot MA
Rev Med Interne; 2010 May; 31(5):361-8. PubMed ID: 20362363
[TBL] [Abstract][Full Text] [Related]
13. [Warfarin resistance and related pharmacogenetic information].
Takahashi H
Brain Nerve; 2008 Nov; 60(11):1365-71. PubMed ID: 19069171
[TBL] [Abstract][Full Text] [Related]
14. Genotype-based dosage of acenocoumarol in highly-sensitive geriatric patients.
Lozano R; Franco ME; López L; Moneva JJ; Carrasco V; Pérez-Layo MA
Int J Clin Pharmacol Ther; 2015 Mar; 53(3):206-10. PubMed ID: 25669612
[TBL] [Abstract][Full Text] [Related]
15. Repeated bleeding complications during therapy with vitamin K antagonists in a patient with the VKORC1*2A and the CYP2C9*3/*3 alleles: genetic testing to support switching to new oral anticoagulants.
Mazur-Bialy AI; Zdebska K; Wypasek E; Undas A
Thromb Res; 2013 Mar; 131(3):279-80. PubMed ID: 23276529
[No Abstract] [Full Text] [Related]
16. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles.
Oldenburg J; Bevans CG; Fregin A; Geisen C; Müller-Reible C; Watzka M
Thromb Haemost; 2007 Sep; 98(3):570-8. PubMed ID: 17849045
[TBL] [Abstract][Full Text] [Related]
17. Effect of different genetics variants: CYP2C9*2, CYP2C9*3 of cytochrome P-450 CYP2C9 and 1639G>A of the VKORC1 gene; On acenocoumarol requirement in Moroccan patients.
Smires FZ; Habbal R; Moreau C; Assaidi A; Loriot MA; Nadifi S
Pathol Biol (Paris); 2013 Jun; 61(3):88-92. PubMed ID: 23201087
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics in cardiovascular diseases: State of the art and implementation-recommendations of the French National Network of Pharmacogenetics (RNPGx).
Lamoureux F; Duflot T;
Therapie; 2017 Apr; 72(2):257-267. PubMed ID: 28237404
[TBL] [Abstract][Full Text] [Related]
19. [Factors influencing the variable response to treatment with oral anticoagulants].
Kucharska K; Popczak G; Prystupa A; Mosiewicz J
Wiad Lek; 2012; 65(1):38-43. PubMed ID: 22827114
[TBL] [Abstract][Full Text] [Related]
20. [Oral anticoagulation and pharmacogenetics: importance in the clinical setting].
Benusiglio PR; Desmeules J; de Moerloose P; Dayer P
Rev Med Suisse; 2007 Sep; 3(124):2030, 2033-4, 2036. PubMed ID: 17955831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
